_id
6921fa04b93c8af7a3933869
Ticker
NBP
Name
NovaBridge Biosciences
Exchange
NASDAQ
Address
2440 Research Boulevard, Rockville, MD, United States, 20850
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.novabridge.com
Description
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Last Close
4.19
Volume
911294
Current Price
3.7
Change
0.29
Last Updated
2026-01-05T11:12:59.060Z
Image
-
Ipo Date
2020-01-17T00:00:00.000Z
Market Cap
-
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9926666666666666
Sentiment Sources
3
Rating
4.2
Strong Buy
1
Buy
4
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
216285
Gross Profit
-216285
Operating Expenses
8989000
Operating Income
-8989000
Interest Expense
-
Pretax Income
-6828000
Net Income
-6828000
Eps
-0.06763560649362445
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
-
EBITDA
-8773000
Operating Margin
-
Total Other Income Expense Net
2161000
Cash
228064000
Short Term Investments
210000
Receivables
926000
Inventories
-
Total Current Assets
232775000
Property Plant Equipment
3165000
Total Assets
277410000
Payables
-
Short Term Debt
872000
Long Term Debt
-
Total Liabilities
18495000
Equity
258915000
Bs_currency_symbol
USD
Depreciation
216285
Change In Working Capital
7007915
Cash From Operations
1846414
Capital Expenditures
5.73
Cash From Investing
-50615
Cash From Financing
60868034
Net Change In Cash
62657126
Cf_currency_symbol
USD
PE
-
PB
1.4426555012262712
ROE
-2.6371589131568274
ROA
-2.4613388125878664
FCF
1846408.27
Fcf Percent
-
Piotroski FScore
2
Health Score
44
Deep Value Investing Score
4.5
Defensive Investing Score
5
Dividend Investing Score
3
Economic Moat Investing Score
5.8
Garp Investing Score
3.5
Growth Investing Score
2
Momentum Investing Score
3
Net Net Investing Score
3.5
Quality Investing Score
4.5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
216285
Quarters > 0 > income Statement > gross Profit
-216285
Quarters > 0 > income Statement > operating Expenses
8989000
Quarters > 0 > income Statement > operating Income
-8989000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-6828000
Quarters > 0 > income Statement > net Income
-6828000
Quarters > 0 > income Statement > eps
-0.06763560649362445
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
100952743
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-8773000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
2161000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
228064000
Quarters > 0 > balance Sheet > short Term Investments
210000
Quarters > 0 > balance Sheet > receivables
926000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
232775000
Quarters > 0 > balance Sheet > property Plant Equipment
3165000
Quarters > 0 > balance Sheet > total Assets
277410000
Quarters > 0 > balance Sheet > payables
-
Quarters > 0 > balance Sheet > short Term Debt
872000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
18495000
Quarters > 0 > balance Sheet > equity
258915000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-6837026
Quarters > 0 > cash Flow > depreciation
216285
Quarters > 0 > cash Flow > change In Working Capital
7007915
Quarters > 0 > cash Flow > cash From Operations
1846414
Quarters > 0 > cash Flow > capital Expenditures
5.73
Quarters > 0 > cash Flow > cash From Investing
-50615
Quarters > 0 > cash Flow > cash From Financing
60868034
Quarters > 0 > cash Flow > net Change In Cash
62657126
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.06763560649362445
Quarters > 0 > ratios > PB
1.4426555012262712
Quarters > 0 > ratios > ROE
-2.6371589131568274
Quarters > 0 > ratios > ROA
-2.4613388125878664
Quarters > 0 > ratios > FCF
1846408.27
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
44
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
7114000
Quarters > 1 > income Statement > operating Income
-7114000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-5504000
Quarters > 1 > income Statement > net Income
-5504000
Quarters > 1 > income Statement > eps
-0.06736901723132752
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
81699277
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-7114000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
1610000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
165404000
Quarters > 1 > balance Sheet > short Term Investments
210000
Quarters > 1 > balance Sheet > receivables
2026000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
167640000
Quarters > 1 > balance Sheet > property Plant Equipment
3381000
Quarters > 1 > balance Sheet > total Assets
206708000
Quarters > 1 > balance Sheet > payables
-
Quarters > 1 > balance Sheet > short Term Debt
853000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
9975000
Quarters > 1 > balance Sheet > equity
196733000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-13267542
Quarters > 1 > cash Flow > depreciation
-
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.06736901723132752
Quarters > 1 > ratios > PB
1.5365359390646207
Quarters > 1 > ratios > ROE
-2.79770043663239
Quarters > 1 > ratios > ROA
-2.662693267798053
Quarters > 1 > ratios > FCF
-
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
42
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
5266000
Quarters > 2 > income Statement > operating Income
-5266000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-3150000
Quarters > 2 > income Statement > net Income
-3150000
Quarters > 2 > income Statement > eps
-0.03860304809177535
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
81599774
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-5266000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2116000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
53597000
Quarters > 2 > balance Sheet > short Term Investments
115025000
Quarters > 2 > balance Sheet > receivables
4611000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
173233000
Quarters > 2 > balance Sheet > property Plant Equipment
3592000
Quarters > 2 > balance Sheet > total Assets
208941000
Quarters > 2 > balance Sheet > payables
-
Quarters > 2 > balance Sheet > short Term Debt
835000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
10600000
Quarters > 2 > balance Sheet > equity
198341000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-22868685
Quarters > 2 > cash Flow > depreciation
-
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.03860304809177535
Quarters > 2 > ratios > PB
1.5222226559309473
Quarters > 2 > ratios > ROE
-1.5881739025214152
Quarters > 2 > ratios > ROA
-1.507602624664379
Quarters > 2 > ratios > FCF
-
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
42
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
12098000
Quarters > 3 > income Statement > operating Income
-12098000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-10844000
Quarters > 3 > income Statement > net Income
-9062000
Quarters > 3 > income Statement > eps
-0.048342914827567376
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
187452495
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-943000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
68263000
Quarters > 3 > balance Sheet > short Term Investments
105135000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
176693000
Quarters > 3 > balance Sheet > property Plant Equipment
3798000
Quarters > 3 > balance Sheet > total Assets
212680000
Quarters > 3 > balance Sheet > payables
-
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
11520000
Quarters > 3 > balance Sheet > equity
201160000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-9062000
Quarters > 3 > cash Flow > depreciation
213000
Quarters > 3 > cash Flow > change In Working Capital
-1130000
Quarters > 3 > cash Flow > cash From Operations
-10949000
Quarters > 3 > cash Flow > capital Expenditures
38000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
0
Quarters > 3 > cash Flow > net Change In Cash
-11064000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.048342914827567376
Quarters > 3 > ratios > PB
3.4478734912507463
Quarters > 3 > ratios > ROE
-4.504871743885464
Quarters > 3 > ratios > ROA
-4.260861388000752
Quarters > 3 > ratios > FCF
-10987000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
37
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
375358000
Annuals > 0 > income Statement > operating Income
-375358000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-362731000
Annuals > 0 > income Statement > net Income
-162257000
Annuals > 0 > income Statement > eps
-1.998581382529021
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
81186086
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-373453000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
12627000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
68263000
Annuals > 0 > balance Sheet > short Term Investments
105135000
Annuals > 0 > balance Sheet > receivables
1172000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
176693000
Annuals > 0 > balance Sheet > property Plant Equipment
3798000
Annuals > 0 > balance Sheet > total Assets
212680000
Annuals > 0 > balance Sheet > payables
-
Annuals > 0 > balance Sheet > short Term Debt
816000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
11520000
Annuals > 0 > balance Sheet > equity
201160000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-49696000
Annuals > 0 > cash Flow > depreciation
978000
Annuals > 0 > cash Flow > change In Working Capital
-2811000
Annuals > 0 > cash Flow > cash From Operations
-52651669
Annuals > 0 > cash Flow > capital Expenditures
48000
Annuals > 0 > cash Flow > cash From Investing
-135970190
Annuals > 0 > cash Flow > cash From Financing
-334889.8
Annuals > 0 > cash Flow > net Change In Cash
-233763464
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-1.998581382529021
Annuals > 0 > ratios > PB
1.7233276358122884
Annuals > 0 > ratios > ROE
-80.66066812487573
Annuals > 0 > ratios > ROA
-76.2916118111717
Annuals > 0 > ratios > FCF
-52699669
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
35
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
4485809
Annuals > 1 > income Statement > cost Of Revenue
0
Annuals > 1 > income Statement > gross Profit
4485809
Annuals > 1 > income Statement > operating Expenses
515647809
Annuals > 1 > income Statement > operating Income
-511162000
Annuals > 1 > income Statement > interest Expense
101854
Annuals > 1 > income Statement > pretax Income
-1465693999
Annuals > 1 > income Statement > net Income
-1465694000
Annuals > 1 > income Statement > eps
-17.610638565786225
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
83227760
Annuals > 1 > income Statement > income Tax Expense
-1258926232
Annuals > 1 > income Statement > EBITDA
-344250000
Annuals > 1 > income Statement > operating Margin
-11395.090606844831
Annuals > 1 > income Statement > total Other Income Expense Net
-954531999
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
2141445000
Annuals > 1 > balance Sheet > short Term Investments
20221000
Annuals > 1 > balance Sheet > receivables
1833000
Annuals > 1 > balance Sheet > inventories
28955000
Annuals > 1 > balance Sheet > total Current Assets
2336669000
Annuals > 1 > balance Sheet > property Plant Equipment
5554000
Annuals > 1 > balance Sheet > total Assets
2612967000
Annuals > 1 > balance Sheet > payables
-
Annuals > 1 > balance Sheet > short Term Debt
51860000
Annuals > 1 > balance Sheet > long Term Debt
8310949.98
Annuals > 1 > balance Sheet > total Liabilities
894811000
Annuals > 1 > balance Sheet > equity
1718156000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-208177290
Annuals > 1 > cash Flow > depreciation
1063290
Annuals > 1 > cash Flow > change In Working Capital
-37202058
Annuals > 1 > cash Flow > cash From Operations
-72853819
Annuals > 1 > cash Flow > capital Expenditures
164354
Annuals > 1 > cash Flow > cash From Investing
-107631000
Annuals > 1 > cash Flow > cash From Financing
-8254780
Annuals > 1 > cash Flow > net Change In Cash
-151581968
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-17.610638565786225
Annuals > 1 > ratios > PB
0.2068395042126559
Annuals > 1 > ratios > ROE
-85.30622364907494
Annuals > 1 > ratios > ROA
-56.09309264143022
Annuals > 1 > ratios > FCF
-73018173
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-16.277592960377937
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
-10697247
Annuals > 2 > income Statement > cost Of Revenue
27237000
Annuals > 2 > income Statement > gross Profit
-248800000
Annuals > 2 > income Statement > operating Expenses
355380753
Annuals > 2 > income Statement > operating Income
-366078000
Annuals > 2 > income Statement > interest Expense
1304.48
Annuals > 2 > income Statement > pretax Income
-973166000
Annuals > 2 > income Statement > net Income
-2507317000
Annuals > 2 > income Statement > eps
-30.385749767745644
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
82516213
Annuals > 2 > income Statement > income Tax Expense
697000
Annuals > 2 > income Statement > EBITDA
-51230000
Annuals > 2 > income Statement > operating Margin
3422.1702088397137
Annuals > 2 > income Statement > total Other Income Expense Net
-607088000
Annuals > 2 > income Statement > currency_symbol
CNY
Annuals > 2 > balance Sheet > cash
3214005000
Annuals > 2 > balance Sheet > short Term Investments
235429000
Annuals > 2 > balance Sheet > receivables
4811502
Annuals > 2 > balance Sheet > inventories
-80278000
Annuals > 2 > balance Sheet > total Current Assets
3626476000
Annuals > 2 > balance Sheet > property Plant Equipment
123966000
Annuals > 2 > balance Sheet > total Assets
4073665000
Annuals > 2 > balance Sheet > payables
-
Annuals > 2 > balance Sheet > short Term Debt
6220486
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
1065339000
Annuals > 2 > balance Sheet > equity
3008326000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-2507317000
Annuals > 2 > cash Flow > depreciation
63816000
Annuals > 2 > cash Flow > change In Working Capital
552064000
Annuals > 2 > cash Flow > cash From Operations
-1102805000
Annuals > 2 > cash Flow > capital Expenditures
45830000
Annuals > 2 > cash Flow > cash From Investing
458382000
Annuals > 2 > cash Flow > cash From Financing
42357000
Annuals > 2 > cash Flow > net Change In Cash
-212863000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-30.385749767745644
Annuals > 2 > ratios > PB
0.11712302107883253
Annuals > 2 > ratios > ROE
-83.34592062163476
Annuals > 2 > ratios > ROA
-61.54941557540937
Annuals > 2 > ratios > FCF
-1148635000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
107.3766923396272
Annuals > 2 > health Score
51
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
88026000
Annuals > 3 > income Statement > cost Of Revenue
46432000
Annuals > 3 > income Statement > gross Profit
41594000
Annuals > 3 > income Statement > operating Expenses
2112900000
Annuals > 3 > income Statement > operating Income
-2071307000
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-2332035814
Annuals > 3 > income Statement > net Income
-2331541000
Annuals > 3 > income Statement > eps
-30.694492041024603
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
75959589
Annuals > 3 > income Statement > income Tax Expense
-494814
Annuals > 3 > income Statement > EBITDA
-2057531000
Annuals > 3 > income Statement > operating Margin
-2353.062731465703
Annuals > 3 > income Statement > total Other Income Expense Net
-260728814
Annuals > 3 > income Statement > currency_symbol
CNY
Annuals > 3 > balance Sheet > cash
3523632000
Annuals > 3 > balance Sheet > short Term Investments
753164000
Annuals > 3 > balance Sheet > receivables
60952291
Annuals > 3 > balance Sheet > inventories
4273073
Annuals > 3 > balance Sheet > total Current Assets
4781718000
Annuals > 3 > balance Sheet > property Plant Equipment
158497000
Annuals > 3 > balance Sheet > total Assets
5629431000
Annuals > 3 > balance Sheet > payables
-
Annuals > 3 > balance Sheet > short Term Debt
30669000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
1041635000
Annuals > 3 > balance Sheet > equity
4587796000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-2331541000
Annuals > 3 > cash Flow > depreciation
34136000
Annuals > 3 > cash Flow > change In Working Capital
394520000
Annuals > 3 > cash Flow > cash From Operations
-973093000
Annuals > 3 > cash Flow > capital Expenditures
29932000
Annuals > 3 > cash Flow > cash From Investing
-727206000
Annuals > 3 > cash Flow > cash From Financing
593924000
Annuals > 3 > cash Flow > net Change In Cash
-1235146000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-30.694492041024603
Annuals > 3 > ratios > PB
0.07069787868292313
Annuals > 3 > ratios > ROE
-50.82050291686902
Annuals > 3 > ratios > ROA
-41.416992232429884
Annuals > 3 > ratios > FCF
-1003025000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-11.394644764046985
Annuals > 3 > health Score
34
Valuation > metrics > PE
-0.06763560649362445
Valuation > metrics > PB
1.4426555012262712
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-2.6371589131568274
Profitability > metrics > ROA
-2.9333046933734295
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.07143270957650194
Risk > metrics > Interest Coverage
-4.621593830334191
Risk > final Score
42
Risk > verdict
High
Liquidity > metrics > Current Ratio
266.94380733944956
Liquidity > metrics > Quick Ratio
266.94380733944956
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
45.52126508749254
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
42
Prev Risks > 1
50
Prev Risks > 2
9
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
50
Updated At
2026-01-20T23:12:04.055Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-13
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.0677
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-20
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.0676
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-15
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.0386
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-12-31
Earnings History > 3 > report Date
2021-03-29
Earnings History > 3 > date
2020-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
2.1923
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-09-30
Earnings History > 4 > report Date
2020-12-02
Earnings History > 4 > date
2020-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
0.0265
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ANovaBridge chairman to purchase up to $5 million in company shares By Investing.com Investing.com Nigeria
Read more →NovaBridge Biosciences' Chairman Plans to Buy $5 Million in ADSs Intellectia AI
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
$
Analyst Picks
Strong Buy
1
Buy
4
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of NovaBridge Biosciences
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.0677
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.